Comparison of the effects of Duphaston and Cetrotide on oocyte and embryo quality in women undergoing ICSI: A cross-sectional study by Motaref, Niloofar et al.
International Journal of Reproductive BioMedicine
Volume 18, Issue no. 11, https://doi.org/10.18502/ijrm.v13i11.7965
Production and Hosting by Knowledge E
Research Article
Comparison of the effects of Duphaston and
Cetrotide on oocyte and embryo quality in
women undergoing ICSI: A cross-sectional
study
Niloofar Motaref M.D., Sheyda Jouhari M.D., Afsaneh Mohammadzadeh M.D.,
Somaieh Kazemnejad M.D., Narges Madadi B.Sc., Sadaf Eghtedari B.Sc.,
Abolfazl Ghoodjani M.Sc.
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Abstract
Background: Premature luteinizing hormone (LH) surge is one of the causes for
assisted reproductive technology cycle cancellation, and it is needed to find novel
approaches with improved efficacy and safety profile.
Objective: To compare the effects of Duphaston and Cetrotide on the prevention of
premature LH surge and characteristics of retrieved follicles and embryos in women
undergoing intracytoplasmic sperm injection.
Materials and Methods: In this retrospective cross-sectional study, 200 patients who
were administrated recombinant follicle-stimulating hormone from the third day of
menstruation cycle were included. When the follicular diameter reached above 13-14
mm, Cetrotide was prescribed in the control group, while in the case group, Duphaston
was taken orally from the third day of cycle. The retrieved oocytes were fertilized in vitro
by intracytoplasmic sperm. The level of hormones on the third day of menstruation and
the characteristic of follicles, oocytes, and embryos were compared between the two
groups.
Results: Duphaston successfully inhibits premature LH surge. There was no significant
difference in the level of follicle-stimulating hormone, estradiol, and LH between the
case and control groups (p > 0.05). However, results also showed that Duphaston
causes more oocyte retrieval in comparison with Cetrotide (p = 0.04). Although, the
number of follicles above 14 mm, mature oocyte, and the total number of viable
embryos in the case group was slightly higher, it did not reach a significant difference
compared with the control group (p > 0.05).
Conclusion: Duphaston could be used as an appropriate medication instead of
gonadotropin-releasing hormone antagonists in women undergoing controlled ovarian
hyperstimulation. Duphaston prescription not only prevents premature LH surge but
also improves the number of retrieved oocytes.
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1. Introduction
About 8-12% of reproductive-aged couples
suffer from infertility worldwide (1). Over the last
decade, assisted reproductive technology (ART)
have drawn considerable attention to overcome
the problem of infertility (2). Interestingly, the
premature luteinizing hormone (LH) surge is one
of the main causes for ART cycle cancellation. In
IVF cases an early surge of LH can compromise
the oocyte resumption (3). In recent years, several
investigations have been done to reduce the
incidence of early LH surge by using gonadotropin-
releasing hormone (GnRH) agonist and antagonists
(4).
Adjuvant therapy with GnRH agonists could
prevent premature LH surge. However, this may
decrease the response to stimulation. Therefore,
higher dose of the drug and long treatment period
would be essential to reach suitable follicular
development (5). In fact, the need for repeated
measurements of serum LH, higher medication
costs, risk of ovarian hyperstimulation syndrome
due to use of higher dose of drugs are the
main disadvantage of GnRH agonist protocols (6).
Therefore, it is necessary to find novel approaches
with improved efficacy, safety profile, and user
convenience.
The initial investigations show that steroidal
products such as oral contraceptive pills and
synthetic progesterone may be an inexpensive
and effective method of preventing LH and
follicle-stimulating hormone (FSH) secretion
(7). Furthermore, it is known that natural and
synthetic progesterone suppress pulsatile GnRH
and LH secretion (8). These effects propose that
progesterone can be used as an alternative to
a GnRH analogue for suppressing premature
LH surge in controlled ovarian hyperstimulation
(COH). One of the synthetic forms of progesterone
is Duphaston (Dydrogesterone), whose molecular
structure and pharmacologic effects are closely
related to endogenous progesterone (9). The
clinical efficiency of Duphaston in progesterone
primed ovarian stimulation (PPOS) regimen were
evaluated by Eftekhar and colleagues (10), who
showed that Duphaston as an FSH adjuvant during
the ovarian stimulation did not lead to similar
mature oocyte retrieval.
The present study was conducted to compare
the efficacy of Duphaston with Cetrotide in
normally ovulating women undergoing COH in
terms of hormone profiles, number of retrieved
oocyte, and embryo quality.
2. Materials and Methods
2.1. Study setting, patients, ovarian
stimulation, and oocyte retrieval
This retrospective cross-sectional study was
conducted at the Avicenna Infertility Clinic
of Tehran and included. Women undergoing
ICSI regimens for infertility treatment between
September 2017 and December 2018. The FSH
and estradiol levels of patients were assessed on
the third day of menstruation in serum, following
which they were divided into case and control
groups.
Infertile women aged 20-40 yr, having an antral
follicle count of at least 4 on the third day of
menstrual cycle, FSH < 12 IU/L, absence of uterine
anomalies and hydrosalpinx, and undergoing IVF
first or second time were deemed eligible for the
study. Whereas, the exclusion criteria of the study
included: evidence of ovarian failure (lack of antral
follicle count in sonography evaluation on the third
day of menstruation), grade 3 or 4 endometriosis,
every contraindication for ovarian stimulation, and
systemic illness such as kidney failure.
A total of 200 patients were assessed for
eligibility (each group 100 patients). Both groups
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were administered 150–225 IU recombinant FSH
(rFSH-Gonal-f Merck Serono, Germany) from the
third day of the menstruation cycle. Follicles were
monitored through transvaginal sonography, 5–
6 days after the gonadotropin stimulation. When
the follicular diameter reached above 13–14 mm,
Cetrotide (0.25 mg/d; Merck Serono, Germany)
was prescribed in the control group, while in
the case group, Duphaston (20 mg/d; Abbott
Healthcare, America) was taken orally from the
third day of cycle until the trigger day. From the
time when three dominant follicles reached > 17
mm, 10,000 IU of hCG (Pooyesh Daroo, Iran) was
prescribed for the final maturation of oocytes and
ovulation. Oocyte retrieval was performed 34–36
hour after the trigger, and the retrieved oocytes
were fertilized in vitro by ICSI.
2.2. Hormone measurement
The level of LH, FSH, estradiol, and
progesterone in the serum were measured by
chemiluminescent method on the third day
of menstruation. A lack of ovulation before
the puncture day was considered as a lack of
premature LH surge.
2.3. Outcome
The number of follicles above 14 mm, number of
oocytes retrieved, their maturation step (Germinal
vesicles, MI and MII), viable embryos and their
grade (A, AB, B, and C) were assessed as the
primary outcome and compared between the
two groups. In this assessment, the embryo was
evaluated according to the Cummins criteria on the
third day of fertilization by number, regularity of
blastomeres, and embryonic fragmentation grade.
The demographic and clinical characteristics such
as age, height, infertility duration, and the number
of IVFs were also collected.
2.4. Ethical consideration
This study was approved by the ethics
committee of the Avicenna Infertility Clinic
(IR.ACECR.avicenna.REC.1397.004). The research-
ers guaranteed that participants’ information
remained anonymous and confidential during the
study period and adhered to the principles of the
Helsinki Declaration and the Ethics Committee
of the Avicenna Infertility Clinic. All participants
provided informed consent after counseling for
infertility treatments and routine IVF procedures.
2.5. Statistical analysis
Data are presented as the Mean ± SD.
Independent t test was applied to analyze the
differences in the outcome of treatment between
the two study groups. All analyses were performed
using the Statistical Package for the Social
Sciences, version 16.0, SPSS Inc, Chicago, Illinois,




This study included 200 patients who were
assigned to either the case group (Duphaston) or
the control group (Cetrotide). The average age
of the control group was 33 ± 4.1 yr and the
case group was 32 ± 4.5 yr, and there were no
significant differences between them (p = 0.26).
The mean BMI in the case and control groups
were 24.61 ± 3.32 and 24.49 ± 3.85, respectively,
which shows no significant alterations between the
two groups (p = 0.37). Further, data analysis also
revealed that there was no significant differences
between groups with respect to the duration
of infertility (3.87 ± 3.85 vs 3.18 ± 3.31 year,
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p = 0.18). The mean number of IVFs in the case and
control groups were 1.29 ± 0.45 and 1.62 ± 0.48,
respectively, which showed that there were no
significant differences between them (p = 0.21).
3.2. Ovarian stimulation, follicles,
oocyte, and embryo grades
The mean stimulation duration and the dose
of rFSH and hCG were similar between the two
groups. Table I compares the number of follicles
above 14 mm, retrieved oocyte, mature (MII) and
immature oocytes (GV and MI), viable embryos
and their grade (A, AB, B, and C) between the
two groups. Values for immature oocyte (MI),
embryo grade AB, and number of retrieved oocytes
were significantly different between the Duphaston
(case) and Cetrotide (control) groups. Also, the
number of follicles above 14 mm, mature oocyte
(MII), total number of viable embryos, embryo
grade B and C in the case group was slightly
higher but did not reach a significant difference
compared with the control group. The number of
GV oocyte and embryos grade A in the control
group was greater than the case group, however,
these differences were not statistically significant.
3.3. Hormone profile
Table II presents the serum concentrations
of FSH, estradiol, and LH on the third day
of menstruation. As seen, on the third day of
the menstrual cycles, there were no significant
differences in level of FSH, estradiol, and LH
between the case and control groups. Neither
the case nor the control group had an oocyte
ovulation before the puncture day. Therefore, it can
be claimed that Duphaston prevents premature LH
surge.
Table I. Stimulation and embryonic characteristics of the case and control group
Characteristic Case (Duphaston) Control (Cetrotide) P-value*
Follicles above 14 mm 9.6 ± 0.56 8.76 ± 0.51 0.25
Retrieved oocytes 13.35 ± 0.85 11.61 ± 0.76 0.04
Immature oocyte (MI) 1.11 ± 0.15 0.51 ± 0.10 < 0.001
Mature oocyte (MII) 11.01 ± 0.56 9.88 ± 0.63 0.20
Immature oocyte (GV) 0.7 ± 0.18 0.9 ± 0.22 0.51
Viable embryos 8.25 ± 0.56 7.34 ± 0.49 0.29
Embryos A 4.45 ± 0.37 4.89 ± 0.43 0.46
Embryos AB 2.08 ± 0.22 1.58 ± 0.18 0.01
Embryos B 0.77 ± 0.16 0.61 ± 0.11 0.43
Embryos C 0.40 ± 0.92 0.28 ± 0.06 0.31
Data presented as Mean ± SD. *Independent t test
Table II. Hormonal level in both groups on the third day of menstruation day
Group FSH Estradiol LH
Case 6.73 ± 0.20 46.26 ± 1.93 6.12 ± 0.48
Control 7.25 ± 0.22 45.94 ± 2.68 6.16 ± 0.66
P-value* 0.11 0.90 0.95
Data presented as Mean ± SE. *Independent t test
FSH: Follicular stimulating hormone; LH: Luteinizing hormone
Page 978 https://doi.org/10.18502/ijrm.v13i11.7965
International Journal of Reproductive BioMedicine Effect of Duphaston and Cetrotide in women undergoing ICSI
4. Discussion
This retrospective cross-sectional study
revealed that in IVF/ICSI cases, oral prescription
of Duphaston can be successfully used as
an alternative to GnRH antagonist in patients
undergoing controlled ovarian stimulation. Our
findings confirmed that an oral delivery of
Duphaston is an effective method in producing
competent oocytes and blocking premature
LH surges. Duphaston is a congener of
progesterone with some but not all of the
effects of progesterone, and it is safe without
androgenic effects even at a high dose (11).
Structural comparison of progesterone and
Duphaston shows that Duphaston contains an
extra double bond between 6- and 7-carbons.
Furthermore, 10-carbon of Duphaston contain
methyl group in α position, while methyl group
on the 10-carbon of progesterone is located
in β position (12, 13). These differences in the
structure enhance the stability and bioavailability
of Duphaston which improves its absorption
and efficiency (14). This study demonstrated
that Duphaston stimulates ovulation in a better
manner and causes more oocyte retrieval in
comparison with Cetrotide. Furthermore, in the
case group who were administered Duphaston,
the number of follicles above 14 mm, mature
oocyte (MII), and the total number of viable
embryos was higher than the control group;
however, these differences were not significant.
These results indicated that Duphaston was
effective on controlled ovarian stimulation
without any complications. These results
are in agreement with previous studies (15,
16).
With regard to the progesterone level and
oocyte/follicles quality, Zavareh and coworker (17)
reported that increase of blood progesterone
concentration may inhibit development of
follicles and oocytes which lead to reduced
fertility potential. Our finding demonstrated that
Duphaston at the used dose in this study not only
had no adverse effect on the development of
follicles and oocytes but also caused more oocyte
retrieval in comparisonwith theGnRHantagonists.
These results are in agreement with the study
of Hamdi and colleagues (18), who showed that
medroxyprogesterone (a form of progesterone)
has no adverse effects on oocyte or follicles
development. It should be mentioned that further
investigation is required to assess the higher dose
of Duphaston or other progesterone congeners
on follicles development. Study also revealed
that no premature LH surge was observed
during COH in patients and it seems Duphaston
had suitable effects on the premature LH surge
control. Additionally, in accordance with this study,
Zhu and co-workers (9) reported no premature
LH surge in patients who used Duphaston for
COH. “The correlation between progesterone
and LH surge is not completely clear. During
COH, multiple follicles grow along with the
dramatically increased estradiol levels, and the
coordinated roles of estrogen and progesterone
may be more powerful for suppressing LH levels”
(3).
Richter and co-authors reported that LH surge
takes place following the activation, transmission,
and the GnRH surge (8, 19). Progesterone prevents
premature LH surge by blocking the GnRH surge
induction system (3). In agreement with this,
it has shown that progestin administration
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during the normal follicular phase results in
decrease of plasma levels of LH (20). Studies
show that estradiol-induced LH surge-generating
signal can be blocked by progesterone in early
stages (immediately after estradiol removal) of
signal transmission (8, 9, 21). Therefore, the
role of progesterone in the LH surge depends
on the time of its administration (17). Results
indicated that to prevent premature LH surge
in IVF cases, Duphaston could be used as an
appropriate medication instead of Cetrotide in
the patients who underwent controlled ovarian
stimulation, because it had no complication
in comparison to Cetrotide and is also more
effective. Duphaston might be a good option
in clinical practice, since oral administration
is more patient-friendly than the injectable
form.
The choice for either should be based mainly
on the availability, cost, and side effects. The
lack of pregnancy and neonatal outcomes
are the limitations of this study. Therefore,
complete additional studies are needed to
provide more evidence about the efficacy of the
Duphaston protocol and to illuminate its impact
on pregnancy and children born from this novel
regimen.
5. Conclusion
Duphaston can be used as an appropriate
medication as an alternative to the GnRH
antagonists. Duphaston prescription not only
prevents premature LH surge but also improves
the number of retrieved follicles and their quality.
Oral administration of Duphaston provides easy
access and better control over LH levels in
comparison with the GnRH antagonists. Following
the additional investigation about optimum
dose and long-term safety of Duphaston,
it could be used as a new regimen for a
controlled ovarian stimulation in freeze-thaw
cycles.
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